Morgan Parker,Mariana Phillips
Morgan Parker
Hyperhidrosis (HH), a condition characterized by excessive sweating beyond thermoregulation, significantly impairs quality of life. Conventional medications to treat HH include aluminum chloride hexahydrate, systemic anticholinergics, and b...
Review
Skin therapy letter. 2026 Mar;31(2):4-7. DOI: 2026
Claire Fason,Stephen Tyring
Claire Fason
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by painful nodules, abscesses, sinus tracts, and scarring, with significant impact on quality of life. Although biologics have expanded treatment ...
Review
Skin therapy letter. 2026 Mar;31(2):1-3. DOI: 2026
Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis [0.03%]
伊科特罗金纳：一种治疗中重度斑块状银屑病的口服IL-23受体抑制剂
Fyona Okundia,Muna Shakhashiro
Fyona Okundia
Biologics have emerged in recent years as relatively safe and effective options for managing plaque psoriasis, however, a subset of patients remain reluctant to initiate biologic therapy. Icotrokinra is a novel, first-in-class oral peptide ...
Review
Skin therapy letter. 2026 Jan;31(1):4-7. DOI: 2026
Alexander Robbins,Mariana Phillips
Alexander Robbins
Alopecia areata (AA), an autoimmune condition characterized by non-scarring hair loss, affects 2% of the United States population. AA is a CD8 T-cell driven autoimmune disease in which the cytokines interferon-gamma and interleukin-15 play ...
Review
Skin therapy letter. 2026 Jan;31(1):1. DOI: 2026
Neoadjuvant Immunotherapy in the Management of Cutaneous Squamous Cell Carcinoma [0.03%]
免疫治疗在皮肤鳞状细胞癌管理中的作用
Christopher Guirguis,Lauren Ching,Mariana Phillips
Christopher Guirguis
Immunotherapy has shown promise in treating locally advanced, recurrent, and metastatic cutaneous squamous cell carcinoma. More recently, studies have shown the role of immunotherapy as neoadjuvant treatment in advanced disease for which su...
Review
Skin therapy letter. 2025 Nov;30(6):10-11. DOI: 2025
OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data [0.03%]
针对中重度特应性皮炎的OX40配体抑制剂：II期临床试验数据述评
Siddhartha Sood,Alim R Devani,Tiago Torres et al.
Siddhartha Sood et al.
Atopic dermatitis (AD) is a common, chronic immune-mediated inflammatory skin disease. The OX40-OX40 ligand (OX40L) pathway has emerged as a novel therapeutic target. On this basis, three phase II clinical trials have been conducted to eval...
Review
Skin therapy letter. 2025 Nov;30(6):1-9. DOI: 2025
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis [0.03%]
乌帕替尼治疗特应性皮炎长期安全性和有效性的评估概述
Mohamad R Taha,Stephen K Tyring
Mohamad R Taha
Atopic dermatitis (AD) is a common inflammatory skin condition characterized by erythema and intense pruritus. A key pathway implicated in its pathogenesis is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) si...
Review
Skin therapy letter. 2025 Sep;30(5):5-7. DOI: 2025
Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib [0.03%]
I型神经纤维瘤病的治疗进展：注重考比替尼的应用
Faith Cormier,Irene Lara-Corrales,Maxwell Sauder et al.
Faith Cormier et al.
Neurofibromatosis type 1 (NF1) is a genetic condition inherited in an autosomal dominant pattern, but with 50% of cases caused by de novo mutations. Neurofibromin, the gene product in NF1, regulates the RAS/MAPK pathway, and mutation can le...
Review
Skin therapy letter. 2025 Sep;30(5):1-4. DOI: 2025
Nanodermatology [0.03%]
纳米皮肤病学
Claire Fason,Stephen K Tyring
Claire Fason
Nanodermatology has been an emerging area of research and drug development in the last two decades. Nanodermatology lies at the intersection of nanotechnology, chemical engineering, biophysics, and pharmacology. Increasing research has yiel...
Review
Skin therapy letter. 2025 Jul;30(4):8-11. DOI: 2025
Leah Johnston,Susan Poelman,Andrei Metelitsa
Leah Johnston
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that ...
Review
Skin therapy letter. 2025 Jul;30(4):1-7. DOI: 2025